Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight

Koomen, J. V., Stevens, J., Mostafa, N. M., Parving, H-H., de Zeeuw, D. & Heerspink, H. J. L., Aug-2018, In : Diabetes obesity & metabolism. 20, 8, p. 2019-2022 4 p.

Research output: Contribution to journalArticleAcademicpeer-review

This study aimed to identify the optimal dose of the endothelin-1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR-JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d of atrasentan in 161 patients with type 2 diabetes and kidney disease. Individual pharmacokinetic parameters were estimated using a population pharmacokinetic approach. Subsequently, changes in the urinary albumin-to-creatinine ratio (UACR) and bodyweight from baseline after 2 weeks' exposure were modelled as a function of the pharmacokinetic parameters. The 0.75 and 1.25 mg doses showed a mean UACR reduction of 34.0% and 40.1%, whereas mean bodyweight increased by 0.9 and 1.1 kg, respectively. A large variation between individuals was observed in the UACR and bodyweight responses. Individual pharmacokinetic parameters correlated significantly with both individual UACR and bodyweight responses (P < .01). The individual response curves for UACR and bodyweight crossed at approximately the mean trough concentration of 0.75 mg atrasentan, indicating that 0.75 mg/d of atrasentan is the optimal dose for kidney protection with maximal efficacy (albuminuria reduction) and safety (minimal sodium retention).

Original languageEnglish
Pages (from-to)2019-2022
Number of pages4
JournalDiabetes obesity & metabolism
Issue number8
Publication statusPublished - Aug-2018

View graph of relations

Download statistics

No data available

ID: 59209915